title: Impact of Donor and Recipient Cytomegalovirus Serostatus on Outcomes of Antithymocyte Globulin-Conditioned Hematopoietic Cell Transplantation.
abstract: Although previous studies involving allogeneic hematopoietic cell transplantation (HCT) without in vivo T cell depletion by rabbit antithymocyte globulin (ATG) have reported a substantial survival difference between D-R- and D+R- patients, but little to no survival difference between D-R+ and D+R+ patients (D, donor; R, recipient; +, cytomegalovirus [CMV] seropositive; -, CMV seronegative), whether this applies to HCT using ATG is unknown. We studied 928 patients who underwent myeloablative HCT for hematologic malignancies in Alberta between 1999 and 2014 who received graft-versus-host disease (GVHD) prophylaxis using ATG (Thymoglobulin, 4.5 mg/kg) in addition to methotrexate and cyclosporine. D-R- and D+R- patients had similar survival (no significant difference). D-R+ patients had a substantially lower survival than D+R+ patients (41% versus 59% at 5 years; P = .001). This difference was attributed to higher nonrelapse mortality, apparently due to higher GVHD-associated mortality. Survival rates were also lower for D-R+ HLA-matched sibling transplant recipients compared with D+R+ HLA-matched unrelated donor transplant recipients (44% versus 66% at 5 years; P = .009). In conclusion, when using ATG, choosing a seronegative donor for a seronegative patient is relatively unimportant, whereas choosing a seropositive donor for a seropositive patient is important, even if this requires the use of a seropositive matched unrelated donor graft.
authors.affiliation: Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada. Electronic address: akalra@ucalgary.ca.
authors.forename: Amit
authors.initials: A
authors.lastname: Kalra
authors.affiliation: Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada.
authors.forename: Tyler
authors.initials: T
authors.lastname: Williamson
authors.affiliation: Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada; Alberta Bone Marrow and Blood Cell Transplant Program, Alberta Health Services, Edmonton, Alberta, Canada.
authors.forename: Andrew
authors.initials: A
authors.lastname: Daly
authors.affiliation: Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada; Alberta Bone Marrow and Blood Cell Transplant Program, Alberta Health Services, Edmonton, Alberta, Canada.
authors.forename: M Lynn
authors.initials: ML
authors.lastname: Savoie
authors.affiliation: Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada; Alberta Bone Marrow and Blood Cell Transplant Program, Alberta Health Services, Edmonton, Alberta, Canada.
authors.forename: Douglas A
authors.initials: DA
authors.lastname: Stewart
authors.affiliation: Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada; Alberta Bone Marrow and Blood Cell Transplant Program, Alberta Health Services, Edmonton, Alberta, Canada.
authors.forename: Faisal
authors.initials: F
authors.lastname: Khan
authors.affiliation: Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada; Alberta Bone Marrow and Blood Cell Transplant Program, Alberta Health Services, Edmonton, Alberta, Canada.
authors.forename: Jan
authors.initials: J
authors.lastname: Storek
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000416:Alberta; D000961:Antilymphocyte Serum / Q000627:therapeutic use*; D002648:Child; D003587:Cytomegalovirus / Q000276:immunology*; D005260:Female; D006086:Graft vs Host Disease / Q000188:drug therapy / Q000401:mortality; D019337:Hematologic Neoplasms / Q000401:mortality / Q000628:therapy; D018380:Hematopoietic Stem Cell Transplantation / Q000009:adverse effects / Q000379:methods*; D006801:Humans; D008297:Male; D008875:Middle Aged; D019653:Myeloablative Agonists / Q000627:therapeutic use; D016036:Seroepidemiologic Studies; D016019:Survival Analysis; D014019:Tissue Donors; D066027:Transplant Recipients; D019172:Transplantation Conditioning / Q000379:methods*; D016896:Treatment Outcome; D055815:Young Adult
chemical_list: D000961:Antilymphocyte Serum; D019653:Myeloablative Agonists
keywords: Antithymocyte globulin; Cytomegalovirus